Patents by Inventor Atta Behfar

Atta Behfar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11413330
    Abstract: This document provides methods and materials for reducing the risk of major adverse cardiac events. For example, methods and materials for identifying patients at risk for experiencing a major adverse cardiac event as well as methods and material for treating patients at risk of experiencing a major adverse cardiac event (e.g., patients who underwent percutaneous coronary intervention (PCT) for ST-elevation myocardial infarction (STEMI) are provided.
    Type: Grant
    Filed: June 3, 2020
    Date of Patent: August 16, 2022
    Assignee: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Atta Behfar, Andre Terzic, Ruben Jose Crespo-Diaz
  • Publication number: 20220241325
    Abstract: Preparations of exosomes and/or Purified Exosome Product (PEP) include antioxidant proteins and antiviral proteins. Compositions that include exosomes and/or PEP can be used to treat subject having, or at risk of having, a condition or tissue damage caused, at least in part, by oxidative stress. Also, compositions that include exosomes and/or PEP can be used to treat subject having, or at risk of having, a viral infection.
    Type: Application
    Filed: July 23, 2020
    Publication date: August 4, 2022
    Applicant: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Timothy Peterson, Atta Behfar, Christopher Paradise
  • Publication number: 20220152084
    Abstract: A composition for delivering a biologic to a subject generally includes a particulate substrate and an mRNA encapsulated by the particulate substrate. In some cases, the mRNA bay be indirectly attached to the particulate substrate. The mRNA encodes at least one therapeutic polypeptide. The composition may be delivered to a tissue of a subject to provide a therapeutic benefit to the tissue.
    Type: Application
    Filed: January 3, 2022
    Publication date: May 19, 2022
    Inventors: Atta Behfar, Andre Terzic
  • Publication number: 20210348128
    Abstract: This document relates to methods and materials for making and using cardiopoetic stem cells. For example, methods and materials for delivering one or more nucleic acids (e.g., one or more RNAs) encoding one or more early mesodermal transcription factors to a stem cell to generate a cardiopoetic stem cell are provided.
    Type: Application
    Filed: September 27, 2019
    Publication date: November 11, 2021
    Inventors: Andre Terzic, Atta Behfar
  • Publication number: 20210277393
    Abstract: A circular RNA molecule generally includes at least one coding region and an internal ribosome entry site (IRES) operably linked to the coding region. The RNA may be more resistant to digestion by an RNA endonuclease that a linear form of the circular RNA. In another aspect, a polynucleotide generally includes a transcription unit and a promoter operably linked to the transcription unit. The transcription unit includes a circularizing element, at least one coding region and an internal ribosome entry site (IRES) operably linked to the coding region. When transcribed by a cell, the transcribed RNA forms a circular RNA molecule.
    Type: Application
    Filed: July 24, 2019
    Publication date: September 9, 2021
    Inventors: Christopher Livia, Atta Behfar, Michael Sabbah
  • Publication number: 20210259969
    Abstract: An extracellular vesicle includes an exogenous therapeutic component. The exogenous therapeutic component can include a therapeutic polypeptide, a polynucleotide that encodes a therapeutic polypeptide, a therapeutic nucleic acid, or a therapeutic agent. In some embodiments, the extracellular vesicle includes an exosome or purified exosome product (PEP).
    Type: Application
    Filed: July 24, 2019
    Publication date: August 26, 2021
    Inventors: Michael Sabbah, Atta Behfar, Christopher Livia, Timothy Peterson
  • Publication number: 20210205229
    Abstract: A platform for introducing a heterologous polynucleotide into a cell so that the cell can express the transcription product of the heterologous polynucleotide includes compositions and methods. The compositions generally include an encapsulating agent and a polynucleotide encapsulated with the encapsulating agent. The encapsulating agent can include a metallic nanoparticle. The polynucleotide includes at least one modification to inhibit degradation of the polynucleotide in cytosol of a cell. In various embodiments, the polynucleotide encodes at least one therapeutic polypeptide or at least one therapeutic RNA. The method includes contacting a composition with a cell and allowing the cell to take up the composition.
    Type: Application
    Filed: May 23, 2019
    Publication date: July 8, 2021
    Inventors: Atta Behfar, Andre Terzic
  • Publication number: 20210169812
    Abstract: A purified exosome product includes spherical or spheroid exosomes with a diameter no greater than 250 nm. In some embodiments, the purified exosome product has a moisture content of no more than 10%. The purified exosome product can be reconstituted to prepare an artificial blood product.
    Type: Application
    Filed: December 14, 2018
    Publication date: June 10, 2021
    Inventors: Atta Behfar, Soulmaz Boroumand, Michael V. Callahan
  • Publication number: 20200353047
    Abstract: This document provides methods and materials for reducing the risk of major adverse cardiac events. For example, methods and materials for identifying patients at risk for experiencing a major adverse cardiac event as well as methods and materials for treating patients at risk of experiencing a major adverse cardiac event (e.g., patients who underwent percutaneous coronary intervention (PCT) for ST-elevation myocardial infarction (STEMI) are provided.
    Type: Application
    Filed: June 3, 2020
    Publication date: November 12, 2020
    Inventors: Atta Behfar, Andre Terzic, Ruben Jose Crespo-Diaz
  • Patent number: 10682394
    Abstract: This document provides methods and materials for reducing the risk of major adverse cardiac events. For example, methods and materials for identifying patients at risk of experiencing a major adverse cardiac event as well as methods and material for treating patients at risk of experiencing a major adverse cardiac event (e.g., patients who underwent percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI) are provided.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: June 16, 2020
    Assignee: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Atta Behfar, Andre Terzic, Ruben Jose Crespo-Diaz
  • Patent number: 10596123
    Abstract: A method of delivering exosomes and other micro vesicles to a biological target includes the steps of 1) providing blood, (2) separating plasma from the provided blood, and (3) separating the solution with the exosomes therefrom, (4) encapsulating the exosomes, and (5) delivering the exosomes. The step of encapsulation may be accomplished by water bead process, alginate bead process, spray drying bead formation, or plating. The biological target may be a human or animal heart, bone/joint, wound or skin. A method of encapsulating an exosome, a method of using an encapsulated exosome, compositions including encapsulated exosomes, and an encapsulated exosome per se are also disclosed.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: March 24, 2020
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Atta Behfar, Andre Terzic, William Cook, Ruben Crespo
  • Publication number: 20190336264
    Abstract: Embolic protection devices can be used to enhance the treatment of heart conditions such as, but not limited to, heart failure and aortic valve stenosis. For example, this document describes percutaneously-deployable intravascular embolic protection devices and methods for their use. The embolic protection devices can be used to capture and remove embolic materials that could otherwise cause adverse patient effects.
    Type: Application
    Filed: December 1, 2017
    Publication date: November 7, 2019
    Applicant: Mayo Foundation for Medical Education and Research
    Inventors: Atta Behfar, David L. Joyce, Mandeep Singh, Andre Terzic
  • Publication number: 20190275071
    Abstract: A composition for delivering a biologic to a subject generally includes a particulate substrate and an mRNA encapsulated by the particulate substrate. In some cases, the mRNA bay be indirectly attached to the particulate substrate. The mRNA encodes at least one therapeutic polypeptide. The composition may be delivered to a tissue of a subject to provide a therapeutic benefit to the tissue.
    Type: Application
    Filed: November 22, 2017
    Publication date: September 12, 2019
    Inventors: Atta Behfar, Andre Terzic
  • Publication number: 20180214518
    Abstract: This document provides methods and materials for reducing the risk of major adverse cardiac events. For example, methods and materials for identifying patients at risk of experiencing a major adverse cardiac event as well as methods and material for treating patients at risk of experiencing a major adverse cardiac event (e.g., patients who underwent percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI) are provided.
    Type: Application
    Filed: December 21, 2017
    Publication date: August 2, 2018
    Inventors: Atta Behfar, Andre Terzic, Ruben Jose Crespo-Diaz
  • Patent number: 9932558
    Abstract: This document relates to compositions containing cardiogenic factors, to methods to obtain cells by culturing initial cells in the presence of such factors; and methods of administering the obtained cells to heart tissue.
    Type: Grant
    Filed: August 6, 2014
    Date of Patent: April 3, 2018
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Andre Terzic, Atta Behfar
  • Patent number: 9884090
    Abstract: This document provides methods and materials for reducing the risk of major adverse cardiac events. For example, methods and materials for identifying patients at risk of experiencing a major adverse cardiac event as well as methods and material for treating patients at risk of experiencing a major adverse cardiac event (e.g., patients who underwent percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI)) are provided.
    Type: Grant
    Filed: September 3, 2014
    Date of Patent: February 6, 2018
    Assignee: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Atta Behfar, Andre Terzic, Ruben Jose Crespo-Diaz
  • Patent number: 9765298
    Abstract: This document provides methods and materials relating to cardiac cells. For example, this document provides methods and materials that can be used to obtain cells having the ability to differentiate into cardiomyocytes. Such cells can be used to repair damaged heart tissue. For example, cells having the ability to differentiate into cardiomyocytes can be used to repair or regenerate heart tissue in patients with a cardiac condition (e.g., ischemic cardiomyopathy, myocardial infarction, or heart failure).
    Type: Grant
    Filed: February 13, 2007
    Date of Patent: September 19, 2017
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Andre Terzic, Atta Behfar
  • Publication number: 20160324794
    Abstract: A method of delivering exosomes and other micro vesicles to a biological target includes the steps of 1) providing blood, (2) separating plasma from the provided blood, and (3) separating the solution with the exosomes therefrom, (4) encapsulating the exosomes, and (5) delivering the exosomes. The step of encapsulation may be accomplished by water bead process, alginate bead process, spray drying bead formation, or plating. The biological target may be a human or animal heart, bone/joint, wound or skin. A method of encapsulating an exosome, a method of using an encapsulated exosome, compositions including encapsulated exosomes, and an encapsulated exosome per se are also disclosed.
    Type: Application
    Filed: March 11, 2016
    Publication date: November 10, 2016
    Inventors: Atta Behfar, Andre Terzic, William Cook, Ruben Crespo
  • Publication number: 20160298086
    Abstract: This document is related to a method for determining the cardio-generative potential of mammalian cells which comprises the assessment of a CARdiac generation Potential Index (CARPI) as a function of the quantification of the expression of genes of said cells. It also relates to a method for quantitatively assessing the modification of this cardio-generative potential and the cardiogenic potential of a treatment aiming at cellular differentiation.
    Type: Application
    Filed: June 21, 2016
    Publication date: October 13, 2016
    Inventors: Andre Terzic, Atta Behfar, Roland Gordon-Beresford, Vinciane Gaussin
  • Publication number: 20160220357
    Abstract: Devices provided herein can include implantable transseptal flow control components adapted to be implanted in an opening in a septal wall. In a closed configuration, the implantable transseptal flow control components provided herein prevent blood from flowing through the opening. In an open configuration, the implantable transseptal flow control components provided herein allow blood to flow from the left atrium to the right atrium. In a closed configuration, implantable transseptal flow control components provided herein can be configured such that blood does not stagnate at a location proximate to a left atrium flow control component side when the pressure differential is below a second predetermined threshold pressure value. Implantable transseptal flow control components provided herein can remain in a closed configuration when a pressure differential between the left atrium and the right atrium is less than a first non-zero predetermined threshold pressure value.
    Type: Application
    Filed: February 4, 2016
    Publication date: August 4, 2016
    Inventors: Umang Anand, Raghav Goel, Roger W. McGowan, Daniel Ross, Patrick A. Haverkost, Mary M. Byron, David R. Wulfman, James P. Rohl, Peter M. Pollak, Lyle J. Olson, Atta Behfar, Charles J. Bruce